IVBIY Projected Dividend Yield
Innovent Biologics Inc ( OTCBB : IVBIY )Innovent Biologics is a biopharmaceutical company engaged in the development and commercialization of biologic therapies. Co. has developed a fully-integrated platform that has enabled it to build a robust pipeline of monoclonal antibodies and other biologics in the fields of oncology, ophthalmology, and autoimmune and metabolic diseases. Co.'s pipeline of 17 antibody drug candidates are led by its four core products that are in late-stage clinical development in China, including sintilimab (IBI-308), Co.'s PD-1 antibody; IBI-305, Co.'s bevacizumab (Avastin) biosimilar; IBI-301, its rituximab (MabThera/Rituxan) biosimilar; and IBI-303, Co.'s adalimumab (Humira) biosimilar. 21 YEAR PERFORMANCE RESULTS |
IVBIY Dividend History Detail IVBIY Dividend News IVBIY Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |